Source: Annual Congress 2006 - Treatment and complications of treatment of lung cancer and malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
V. Kacar-Kukric, S. Popevic (Belgrade, Serbia And Montenegro). Cancer recurrence in surgically treated non small cell lung cancer (NSCLC). Eur Respir J 2006; 28: Suppl. 50, 4332

Member's Comments

No comment yet.

Related content which might interest you: Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Lung cancer Source: Respipedia Article Year: 2018 How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Imaging in oncology and infectious diseases Year: 2011 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Disease relapse in surgically and conservatively treated patients with stage I-II of non-small cell lung cancer Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Chemotherapy in advanced non small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Surveillance imaging and recurrence rates following surgery for non-small cell lung cancer (NSCLC). Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020